Find recruiting clinical trials for NSCLC in the UK � including adenocarcinoma, squamous cell, and large cell subtypes. See your treatment pathway and where trials fit in.
Free to use � Live data from ClinicalTrials.gov � Updated hourly
Answer a few questions about your condition and we'll match you to the most relevant clinical trials.
See where clinical trials fit into your treatment journey
Initial treatment after diagnosis of advanced or metastatic NSCLC
Standard: Chemotherapy + Immunotherapy (e.g. Pembrolizumab + Carboplatin + Pemetrexed)
After progression on 1st-line therapy
Standard: Immunotherapy or Docetaxel � Ramucirumab
After multiple progressions � clinical trials are especially important here
Standard: Clinical trial enrollment or salvage therapy
Ongoing treatment after initial response
Standard: Pembrolizumab or Pemetrexed maintenance
Non-Small Cell Lung Cancer accounts for about 85% of all lung cancers. Subtypes include adenocarcinoma (most common), squamous cell carcinoma, and large cell carcinoma.
Lung cancer treatment is evolving rapidly. New immunotherapies, targeted therapies, and combination treatments are being tested that may improve outcomes compared to standard care.
Eligibility depends on your specific subtype, stage, biomarker status (PD-L1, EGFR, ALK, KRAS), prior treatments, and overall health. Each trial has specific criteria.
Loading trials from ClinicalTrials.gov...
Active targets include EGFR mutations (Osimertinib successors), ALK rearrangements, ROS1, BRAF, MET exon 14 skipping, RET fusions, and KRAS G12C. Many next-generation targeted drugs are in UK trials.
Yes. Immunotherapy (Pembrolizumab, Nivolumab, Atezolizumab) is standard first-line treatment for many NSCLC patients. Trials study new combinations, bispecific antibodies, and personalised immunotherapy approaches.
Most modern NSCLC trials require molecular profiling of your tumour to match you with the right targeted therapy. Comprehensive genomic testing is increasingly available on the NHS.
Use our search above to find trials that match your condition and location. Review the eligibility criteria carefully.
Talk to your GP or specialist about any trials you are interested in. They can help determine if a trial is appropriate for you.
Reach out to the trial team directly using the contact information on the ClinicalTrials.gov listing. They will guide you through screening.
If you meet the criteria and decide to participate, you will go through informed consent and begin the trial process.
Learn about EGFR inhibitors, KRAS G12C targeted therapy, immunotherapy combinations, ADCs, and neoadjuvant approaches for NSCLC.
NSCLC Clinical Trials UK (2026) →